Introduction {#JVEv4-sec-0001}
============

Hepatitis C virus (HCV) represents a considerable morbidity and cost burden, contributing to approximately 400,000 deaths annually worldwide [@JVEv4-bib-0001], and estimated yearly costs of at least US\$6.5 billion in the United States [@JVEv4-bib-0002]. Given the advent of all-oral direct-acting antiviral agents (DAAs) to treat HCV, with lower toxicity and no injections such as those required with interferon-based regimens, it is possible to reduce mortality associated with HCV [@JVEv4-bib-0003] and to extend therapy to people who may have previously been reticent to undergo treatment [@JVEv4-bib-0004]. The goal of HCV therapy is attainment of sustained virological response (SVR), defined as undetectable RNA levels in the blood 12 weeks after treatment completion. Patients who attain SVR are considered cured, thus avoiding HCV-related mortality and morbidity [@JVEv4-bib-0005].

A significant reduction in HCV incidence and prevalence will require treatment for people who use drugs (PWUD), as injection drug use comprises the most common mode of HCV transmission [@JVEv4-bib-0006]. The mean burden of HCV among PWUD is estimated to be approximately 60%, with HCV prevalence varying between 25% and 90% depending on local prevalence patterns [@JVEv4-bib-0007]. In addition to curing the therapy recipient of HCV, that person can then no longer transmit HCV, thus preventing HCV transmission to other PWUD [@JVEv4-bib-0008]. HCV treatment among PWUD can be cost-effective [@JVEv4-bib-0009], since treatment can negate HCV-related sequelae such as cirrhosis and hepatocellular carcinoma, which HCV-infected PWUD are likely to develop in mid to late adulthood [@JVEv4-bib-0010].

PWUD may not receive treatment as a result of clinician concerns about compliance with the treatment regimen, and the possibility of HCV re-infection following a course of antiHCV treatment [@JVEv4-bib-0011]. Effectively treating PWUD for HCV requires both a significant increase in treatment availability, for example by incorporating treatment into methadone maintenance therapy, and uptake by patients who may be distrustful of healthcare systems or unable to adhere to regimens due to unmet social needs [@JVEv4-bib-0004]. Additionally, it is important to note that the treatment-as-prevention strategy is successful in lower-HCV prevalence areas compared to those with higher HCV prevalence [@JVEv4-bib-0014], and thus care models may need to be adapted to local populations. Clearly, creative models of treatment delivery are needed to reach PWUD who are infected with HCV.

Directly observed therapy (DOT) is a care delivery model that was first established for treatment of tuberculosis [@JVEv4-bib-0015] and was then adapted to deliver treatment to people infected with HIV [@JVEv4-bib-0016]. DOT has been shown to deliver effective HCV treatment in prisons, primary care clinics, hepatology clinics, drug treatment facilities and multidisciplinary health centres [@JVEv4-bib-0017]. Prior reviews have assessed ways to deliver HCV treatment to PWUD, looking at predictors of treatment completion or HCV treatment delivery mechanisms [@JVEv4-bib-0021]. Given the potential of DOT to deliver treatment among PWUD [@JVEv4-bib-0009], we conducted a systematic review and summarised existing literature on DOT used in outpatient programmes and SVR attainment in HCV-infected PWUD using meta-analytic techniques. We report our results to augment the available data to inform treatment strategies.

Methods {#JVEv4-sec-0002}
=======

We performed this meta-analysis following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [@JVEv4-bib-0023]. Our study protocol is registered with PROSPERO (registration number CRD42014012957).

Data sources {#JVEv4-sec-0003}
------------

We performed a comprehensive search for eligible studies, searching the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and references of relevant articles from the start of each respective database through to the end of August 2017. We also reviewed the conference proceedings and websites of professional organisations such as the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA). We used the following search strategy: ('directly observed therapy'\[MeSH Terms\] OR ('directly'\[All Fields\] AND 'observed'\[All Fields\] AND 'therapy'\[All Fields\]) OR 'directly observed therapy'\[All Fields\]) AND ('hepatitis c'\[MeSH Terms\] OR 'hepatitis c'\[All Fields\] OR 'hepacivirus'\[MeSH Terms\] OR 'hepacivirus'\[All Fields\]). We manually searched the reference lists of included studies and related systematic reviews. Two abstractors (CM, CL) evaluated and coded eligible studies. The lead author contacted abstract authors to obtain study results if available.

Study selection {#JVEv4-sec-0004}
---------------

We report our study selection parameters following the PICOTS (Patient population, Intervention, Comparator, Outcome, Timing, Setting) framework. Our study population includes adults (ages 18 and over) with chronic or acute HCV infection of any genotype and who were either receiving opioid maintenance therapy or actively using illicit, injected drugs such as heroin. For our meta-analysis, we included studies that used randomisation and had a comparison arm. The intervention of interest is the randomised DOT assignment for administration of HCV antiviral medications. HCV antiviral medications of interest include pegylated interferon (PEG-IFN)/ribavirin-based regimens as well as the newer direct-acting agents, including NS3/4A protease inhibitors (grazoprevir, paritaprevir, simeprevir), NS5A inhibitors (daclatasvir, elbasvir, ledipasvir, ombitasvir, velpatasvir), or NS5B inhibitors (dasabuvir, sofosbuvir), as single agents or in combination (e.g. ledipasvir/sofosbuvir).

The definition of 'directly observed therapy' can be heterogeneous, with different interventions labelled as DOT or similar principles applied without describing them as DOT. For this analysis, we defined DOT as treatment receipt during which time the patient was observed to consume an oral medication and/or receive an injection while in the presence of nursing, community health worker or other trained staff. The comparison group is patients with HCV receiving treatment as usual, receiving at least one of the aforementioned antiviral medications but either not directly observed by study staff or after a time delay for further assessment of subjects\' suitability for treatment.

Our outcome of interest is the odds of attaining SVR. We searched for studies that followed patients for at least 12 weeks after treatment completion. We included studies conducted in the setting of outpatient clinics. We excluded studies performed in institutional settings or prisons, as the goal of this analysis is to evaluate the effectiveness of DOT provided in outpatient settings rather than closed systems.

Analysis {#JVEv4-sec-0005}
--------

Two reviewers (CM, CL) assessed study bias using the Cochrane Collaboration\'s risk of bias tool for randomised studies and the ROBINS-I tool for observational studies [@JVEv4-bib-0024]. We assessed the strength of evidence overall using the GRADE scheme [@JVEv4-bib-0025]. We performed a meta-analysis using the DerSimonian and Laird random-effects model with pooled odds ratios (OR) for the odds of SVR attainment [@JVEv4-bib-1001]. We performed a sensitivity analysis to see how the inclusion of observational studies comparing DOT and SVT that did not use randomisation affected our findings. We conducted our analysis using Stata version 15 (College Station, TX, USA).

Results {#JVEv4-sec-0006}
=======

In our database search we identified 690 potentially eligible studies (Figure [1](#JVEv4-fig-0001){ref-type="fig"}). We eliminated 44 duplicates (e.g. appearing in both Medline and Embase), resulting in 646 titles for review. After conducting a title review to assess appropriateness for this analysis, we eliminated 593 records. We pulled 53 abstracts for abstract review; of these, 24 were not pertinent to our study question. We deemed 28 studies and one abstract to be a potential fit for our inclusion criteria. Following a full-text review, six studies met our inclusion criteria of comparing DOT to treatment as usual and we report the characteristics of those studies in Table [1](#JVEv4-tbl-0001){ref-type="table"}. For our meta-analysis, we included four studies that randomised patients to treatment (Figure [1](#JVEv4-fig-0001){ref-type="fig"}). Of the six studies in this systematic review, four studies were performed in the United States, one in Canada, and one in Italy (Table [1](#JVEv4-tbl-0001){ref-type="table"}). All patients received ribavirin in combination with PEG-IFN. Across all studies, 242 patients received DOT and 165 received treatment as usual. In our meta-analysis, we included a total of 124 subjects receiving DOT and 91 receiving treatment as usual.

![PRISMA flow diagram detailing inclusion and exclusion criteria for studies [@JVEv4-bib-0023]](JVE-4-118-g001){#JVEv4-fig-0001}

###### 

Studies identified in systematic review and characteristics of each study population

  Author \[ref\]                Country   Year   Study type              Outpatient setting                                                           Genotypes      DOT Treatment                                                     TAU                                                                                                   Outcome   Number enrolled   
  ----------------------------- --------- ------ ----------------------- ---------------------------------------------------------------------------- -------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- --------- ----------------- ----
  Bonkovsky [@JVEv4-bib-0039]   USA       2008   Randomised open-label   Six study sites; methadone clinics and outpatient clinics within each site   1--3           Self-administered RBV, provider-administered weekly PEG-IFN       Self-administered RBV, first PEG-IFN injection provider-administered then self-administered PEG-IFN   SVR       24                24
  Bruce [@JVEv4-bib-0040]       USA       2012   RCT                     One site with a methadone clinic and a hepatology clinic                     1--4           Provider administered weekly PEG-IFN with RBV in MEMS container   Self-administered PEG-IFN and RBV in MEMS containers                                                  SVR       12                9
  Hilsden [@JVEv4-bib-0041]     Canada    2013   Randomised open-label   Two urban outpatient health clinics                                          1--3           Self-administered RBV, provider-administered weekly PEG-IFN       Self-administered RBV, provider-administered weekly PEG-IFN after a delay in treatment initiation     SVR       48                18
  Litwin [@JVEv4-bib-0042]      USA       2010   RCT                     Nine outpatient methadone clinics                                            Not reported   Directly observed RBV, provider-administered weekly PEG-IFN       Self-administered RBV, provider-administered weekly PEG-IFN                                           SVR       40                40
  Cioe [@JVEv4-bib-0019]        USA       2013   Retrospective cohort    Two hospital outpatient clinics: primary care and hepatology                 Not reported   Self-administered RBV, provider-administered weekly PEG-IFN       Self-administered PEG-IFN and RBV                                                                     SVR       97                58
  Nosotti [@JVEv4-bib-0026]     Italy     2014   Prospective cohort      One outpatient drug treatment clinic                                         Not reported   Directly observed RBV, provider-administered weekly PEG-IFN       Self-administered RBV and PEG-IFN                                                                     SVR       21                16

DOT: directly observed therapy; MEMS: medication event monitoring system; PEG-IFN: pegylated interferon; RBV: ribavirin; RCT: randomised controlled trial; SVR: sustained virological response; TAU: treatment as usual.

The odds of attaining SVR using DOT were twice that of treatment as usual (odds ratio 2.01, 95% confidence interval \[CI\] 1.13-- 3.59, Figure [2](#JVEv4-fig-0002){ref-type="fig"}). Our *I^2^* was 0.2% (*P*=0.39). In our sensitivity analysis, the inclusion of a retrospective cohort study [@JVEv4-bib-0019] and a prospective study [@JVEv4-bib-0026] that compared DOT versus treatment as usual without randomisation changed the results. The odds of achieving SVR using DOT were 1.51, but were no longer significant (95% CI 0.97--2.34).

![Odds of sustained virological response attainment for those receiving directly observed therapy versus treatment as usual: Der Simonian and Laird Random Effects Model](JVE-4-118-g002){#JVEv4-fig-0002}

We rated the randomised studies as having an unclear risk of bias, and the observational studies as having moderate or critical bias (Table [2](#JVEv4-tbl-0002){ref-type="table"}). The studies did not report any details about sequence generation or allocation concealment. No studies described blinding of participants or study personnel. Three studies were listed with a [ClinicalTrials.gov](ClinicalTrials.gov) entry. Two studies were funded by the US National Institute on Drug Abuse, one by the pharmaceutical industry, and one by HealthCanada with medication supplied by a pharmaceutical company. We found the overall strength of evidence to be moderate.

###### 

Assessment of bias for each study, using the Cochrane Collaboration\'s tool for assessing risk of bias for randomised studies and the ROBINS-I bias tool for observational studies

  Randomised studies                                                                        
  ----------------------------- --------- --------- --------- --------- --------- --------- ---------
  Bonkovsky [@JVEv4-bib-0039]   Unclear   Unclear   No        Yes       Yes       Unclear   Unclear
  Bruce [@JVEv4-bib-0040]       Unclear   Unclear   No        Yes       Yes       Unclear   Unclear
  Hilsden [@JVEv4-bib-0041]     Yes       Unclear   No        No        Unclear   Unclear   Unclear
  Litwin [@JVEv4-bib-0042]      Unclear   Unclear   Unclear   Unclear   Unclear   Unclear   Unclear

  Observational studies                                                                                  
  --------------------------- ---------- ---------- ---------- ---------- --------- ---------- --------- ----------
  Cioe [@JVEv4-bib-0019]      Moderate   Moderate   Moderate   Moderate   Low       Moderate   Low       Moderate
  Nosotti [@JVEv4-bib-0026]   Serious    Critical   Moderate   Serious    Serious   Serious    Serious   Critical

Discussion {#JVEv4-sec-0007}
==========

Given the burden of HCV among PWUD and the advent of newer therapies that may decrease this burden [@JVEv4-bib-0027], research that identifies the most effective strategies to deliver such medication to PWUD is needed. While previously conducted pre--post studies that evaluated DOT as a means to achieve SVR using older HCV medications (e.g. PEG-IFN and ribavirin) showed a positive association between DOT and SVR, with the percentage of patients attaining SVR ranging from 55% [@JVEv4-bib-0017] to 65% [@JVEv4-bib-0028], up to 94% [@JVEv4-bib-0029] and 98% [@JVEv4-bib-0018], observational studies comparing DOT to treatment as usual have had more mixed results, with patients receiving DOT having similar SVR to those receiving treatment as usual [@JVEv4-bib-0019]. We conducted this meta-analysis to increase sample size available for analysis and summarise the quality of and findings of available studies.

We found a statistically significant increase in attainment of SVR among individuals receiving DOT while receiving opioid maintenance therapy and/or actively injecting drugs. While other systematic reviews and meta-analyses have evaluated treatment completion determinants among PWUD or HCV treatment delivery mechanisms for PWUD [@JVEv4-bib-0021], we filled a knowledge gap by assessing the association between DOT and SVR as an outcome, focusing on randomised studies with a comparator group. In our pooled analysis, 58% of people receiving DOT and 39% of those receiving treatment as usual attained SVR. A recent prospective, observational trial found that while PWUD had a high rate of discontinuation of PEG-IFN/ribavirin therapy, those who completed treatment had SVR attainment rates similar to other cohorts [@JVEv4-bib-0030].

DOT in conjunction with other services can help connect PWUD with treatment while meeting social and medical needs. One study randomised pharmacies in Scotland to screen for HCV among people receiving outpatient methadone therapy, then allowed pharmacists to prescribe ledipasvir/sofosbuvir to facilitate HCV treatment [@JVEv4-bib-0031]. Another study used community health workers to observe HCV therapy among patients, varying the medications received while all subjects received DOT. Patients receiving sofosbuvir plus PEG-IFN and ribavirin achieved 100% SVR while 68% of patients receiving sofosbuvir plus ribavirin attained SVR [@JVEv4-bib-0032]. As all study subjects received DOT simultaneously without a comparison to those not receiving DOT, this study was not included in our analysis.

While the dominant paradigm has been to deliver HCV treatment to PWUD in the setting of methadone clinics, furthering the reach of HCV treatment, such as using pharmacists and innovative health models, reaches more PWUD. Treatment among PWUD with newer agents may be cost-effective, but this depends on the number of PWUD who are reached with treatment [@JVEv4-bib-0033]. A recent systematic review showed that community-based HCV treatment, when compared to treatment received in a tertiary care centre such as a hospital, is effective with respect to treatment uptake and SVR achievement [@JVEv4-bib-0034]. As DAA receipt is most effective in PWUDs when liver fibrosis has not progressed [@JVEv4-bib-0035], delivering care in this population in a timely fashion following diagnosis may help decrease HCV-related complications.

Our study has multiple strengths, including a focus on randomised studies with a comparator group, interventions delivered in outpatient settings rather than closed settings such as prisons, and assessing the relationship between DOT and SVR. We also note several limitations to our study. As few studies met our inclusion criteria, we were unable to control for confounding using meta-regression techniques. Accordingly, the studies that included the smallest number of participants were assigned less weight in the meta-analysis. All studies included herein involved PEG-IFN/ribavirin, which has a more significant side-effect profile and disutility associated with injection when compared to the newer, oral agents. Future evaluations that include only oral agents delivered by DOT may find even greater increased odds of achieving SVR, and should be the focus of future research in PWUD.

Treating PWUD is an essential component of any plan to eradicate HCV in the future [@JVEv4-bib-0036], especially since prevalence of HCV is rising in some areas of the world and has only seen a small decline in other parts [@JVEv4-bib-0001]. Care models that provide HCV treatment to PWUD must be flexible and incorporate different services to meet the needs of this population [@JVEv4-bib-0037], as noted in a recent call for further research to include evaluation of models of care to reach PWUD and enhance treatment [@JVEv4-bib-0038]. This study augments the available literature indicating that DOT may further facilitate treatment uptake among PWUD, and provides researchers and policymakers with additional information to inform future interventions.
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